James Lindsay is the Professor of Inflammatory Bowel Disease at Barts and the London School of Medicine and Dentistry, Queen Mary University of London and a Consultant Gastroenterologist at Barts Health NHS Trust. Along with a full multidisciplinary team he runs the adolescent and adult IBD service at The Royal London Hospital.
He is the Education Officer and a member of the Governing Board of the European Crohn’s and Colitis Organisation (ECCO). He is also the ECCO e-learning ambassador and past chair of the ECCO Education Committee. He has chaired working groups for the ECCO consensus on the management of Crohn’s disease and ulcerative colitis. He is the British Society of Gastroenterology (BSG) national societies representative to United European Gastroenterology and is a member of the International Organisation of IBD (IOIBD)
Professor Lindsay serves on the BSG IBD Clinical Trials Steering Group and is Chief Investigator for a series of investigator-led and commercial clinical trials in IBD. He leads the NIHR funded ASTIClite trial which will assess the efficacy, safety and mechanism of action of low intensity autologous stem cell transplantation in patients with refractory Crohn’s disease. In addition, he leads a program of translational science research.
Experience
-
2017–presentChair professor, Queen Mary University of London
Education
-
2008Royal College of Physicians, FRCP
-
2002Imperial College London, PhD
-
1993University Of Oxford, BM BCh
-
1990University of Cambridge, BA
Publications
-
2016One year outcome of autologous stem cell transplantation in treatment refractory Crohn’s disease: identifying factors that predict benefit and harm, Lancet Gastroenterology and Hepetology
-
2015Autologous Haemopoetic Stem Cell Transplantation for refractory Crohn disease: a randomised clinical trial, JAMA
Professional Memberships
- Education Officer and Governing Board European Crohn's and Colitis Organisation
- International Organisation for IBD (IOIBD) member
- Website
- Article Feed
- Joined
